Clinical evolution after relapse
| . | RT-PCR result . | ||
|---|---|---|---|
| Negative, no. (%) . | Low-level positive, no. (%) . | High-level positive, no. (%) . | |
| Treatment of relapse | |||
| DLI | 8 (57) | 7 (62) | 34 (65) |
| Other | 6 (43) | 1 (38) | 18 (35) |
| Disease status at DLI | |||
| Molecular/cytogenetic | 6 (75) | 3 (43) | 12 (35) |
| Hematologic | 2 (25) | 4 (57) | 22 (65) |
| Response to DLI | |||
| Molecular remission | 4 (50) | 5 (72) | 14 (41) |
| No response | 2 (25) | 1 (14) | 13 (38) |
| Not yet evaluable | 2 (25) | 1 (14) | 7 (21) |
| . | RT-PCR result . | ||
|---|---|---|---|
| Negative, no. (%) . | Low-level positive, no. (%) . | High-level positive, no. (%) . | |
| Treatment of relapse | |||
| DLI | 8 (57) | 7 (62) | 34 (65) |
| Other | 6 (43) | 1 (38) | 18 (35) |
| Disease status at DLI | |||
| Molecular/cytogenetic | 6 (75) | 3 (43) | 12 (35) |
| Hematologic | 2 (25) | 4 (57) | 22 (65) |
| Response to DLI | |||
| Molecular remission | 4 (50) | 5 (72) | 14 (41) |
| No response | 2 (25) | 1 (14) | 13 (38) |
| Not yet evaluable | 2 (25) | 1 (14) | 7 (21) |
RT-PCR indicates reverse transcriptase–polymerase chain reaction; DLI, donor lymphocyte infusion.